Cargando…

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus

A new variant of SARS-CoV-2 B.1.351 lineage (first found in South Africa) has been raising global concern due to its harboring of multiple mutations in the spike that potentially increase transmissibility and yield resistance to neutralizing antibodies. We here tested infectivity and neutralization...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yeong Jun, Jang, Ui Soon, Soh, Sandrine M., Lee, Joo-Youn, Lee, Hye-Ra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067879/
https://www.ncbi.nlm.nih.gov/pubmed/33917138
http://dx.doi.org/10.3390/v13040633
_version_ 1783682905882492928
author Kim, Yeong Jun
Jang, Ui Soon
Soh, Sandrine M.
Lee, Joo-Youn
Lee, Hye-Ra
author_facet Kim, Yeong Jun
Jang, Ui Soon
Soh, Sandrine M.
Lee, Joo-Youn
Lee, Hye-Ra
author_sort Kim, Yeong Jun
collection PubMed
description A new variant of SARS-CoV-2 B.1.351 lineage (first found in South Africa) has been raising global concern due to its harboring of multiple mutations in the spike that potentially increase transmissibility and yield resistance to neutralizing antibodies. We here tested infectivity and neutralization efficiency of SARS-CoV-2 spike pseudoviruses bearing particular mutations of the receptor-binding domain (RBD) derived either from the Wuhan strains (referred to as D614G or with other sites) or the B.1.351 lineage (referred to as N501Y, K417N, and E484K). The three different pseudoviruses B.1.351 lineage related significantly increased infectivity compared with other mutants that indicated Wuhan strains. Interestingly, K417N and E484K mutations dramatically enhanced cell–cell fusion than N501Y even though their infectivity were similar, suggesting that K417N and E484K mutations harboring SARS-CoV-2 variant might be more transmissible than N501Y mutation containing SARS-CoV-2 variant. We also investigated the efficacy of two different monoclonal antibodies, Casirivimab and Imdevimab that neutralized SARS-CoV-2, against several kinds of pseudoviruses which indicated Wuhan or B.1.351 lineage. Remarkably, Imdevimab effectively neutralized B.1.351 lineage pseudoviruses containing N501Y, K417N, and E484K mutations, while Casirivimab partially affected them. Overall, our results underscore the importance of B.1.351 lineage SARS-CoV-2 in the viral spread and its implication for antibody efficacy.
format Online
Article
Text
id pubmed-8067879
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80678792021-04-25 The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus Kim, Yeong Jun Jang, Ui Soon Soh, Sandrine M. Lee, Joo-Youn Lee, Hye-Ra Viruses Communication A new variant of SARS-CoV-2 B.1.351 lineage (first found in South Africa) has been raising global concern due to its harboring of multiple mutations in the spike that potentially increase transmissibility and yield resistance to neutralizing antibodies. We here tested infectivity and neutralization efficiency of SARS-CoV-2 spike pseudoviruses bearing particular mutations of the receptor-binding domain (RBD) derived either from the Wuhan strains (referred to as D614G or with other sites) or the B.1.351 lineage (referred to as N501Y, K417N, and E484K). The three different pseudoviruses B.1.351 lineage related significantly increased infectivity compared with other mutants that indicated Wuhan strains. Interestingly, K417N and E484K mutations dramatically enhanced cell–cell fusion than N501Y even though their infectivity were similar, suggesting that K417N and E484K mutations harboring SARS-CoV-2 variant might be more transmissible than N501Y mutation containing SARS-CoV-2 variant. We also investigated the efficacy of two different monoclonal antibodies, Casirivimab and Imdevimab that neutralized SARS-CoV-2, against several kinds of pseudoviruses which indicated Wuhan or B.1.351 lineage. Remarkably, Imdevimab effectively neutralized B.1.351 lineage pseudoviruses containing N501Y, K417N, and E484K mutations, while Casirivimab partially affected them. Overall, our results underscore the importance of B.1.351 lineage SARS-CoV-2 in the viral spread and its implication for antibody efficacy. MDPI 2021-04-07 /pmc/articles/PMC8067879/ /pubmed/33917138 http://dx.doi.org/10.3390/v13040633 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Kim, Yeong Jun
Jang, Ui Soon
Soh, Sandrine M.
Lee, Joo-Youn
Lee, Hye-Ra
The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
title The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
title_full The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
title_fullStr The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
title_full_unstemmed The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
title_short The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
title_sort impact on infectivity and neutralization efficiency of sars-cov-2 lineage b.1.351 pseudovirus
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067879/
https://www.ncbi.nlm.nih.gov/pubmed/33917138
http://dx.doi.org/10.3390/v13040633
work_keys_str_mv AT kimyeongjun theimpactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT janguisoon theimpactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT sohsandrinem theimpactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT leejooyoun theimpactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT leehyera theimpactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT kimyeongjun impactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT janguisoon impactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT sohsandrinem impactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT leejooyoun impactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus
AT leehyera impactoninfectivityandneutralizationefficiencyofsarscov2lineageb1351pseudovirus